SRR12202429
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.520
- SPERMATOGENESIS+0.360
- PROTEIN_SECRETION+0.350
- E2F_TARGETS+0.230
- KRAS_SIGNALING_DN+0.220
- ANDROGEN_RESPONSE+0.180
- G2M_CHECKPOINT+0.110
- BILE_ACID_METABOLISM+0.100
- COAGULATION+0.070
- FATTY_ACID_METABOLISM+0.070
Top 10 suppressed
- MYC_TARGETS_V2-0.480
- WNT_BETA_CATENIN_SIGNALING-0.460
- P53_PATHWAY-0.370
- INTERFERON_ALPHA_RESPONSE-0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.350
- APICAL_JUNCTION-0.300
- DNA_REPAIR-0.300
- HEDGEHOG_SIGNALING-0.290
- INTERFERON_GAMMA_RESPONSE-0.290
- NOTCH_SIGNALING-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG731 | — | — | 0.831 |
| 2 | R141 | — | — | 0.785 |
| 3 | 66326_S124 | — | cohortA1 | 0.782 |
| 4 | MNG1185 | — | — | 0.778 |
| 5 | SRR33346963 | — | — | 0.767 |
| 6 | 026991e0-4791-4eb9-8817-54e0fdee5bcb | — | — | 0.762 |
| 7 | TCGA-D8-A1XV-01A-11R-A14M-07 | — | B | 0.760 |
| 8 | TCGA-LT-A5Z6-01A-11R-A28M-07 | — | — | 0.756 |
| 9 | SRR12202430 | — | — | 0.752 |
| 10 | R411 | — | — | 0.747 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.520 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.360 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.180 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.110 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.070 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.010 | Inavolisib | — uncovered |